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Abstract
Aims: Increased levels of homocysteine (Hcy) form
an independent risk factor for cardiovascular disease.
In a previous study we have shown that Hcy induced
phosphatidylserine (PS) exposure to the outer leaflet
of the plasma membrane in cardiomyocytes, inducing
a pro-inflammatory phenotype. In the present study
the mechanism(s) involved in Hcy-induced PS
exposure were analyzed. Methods: H9c2 rat
cardiomyoblasts were subjected to 2.5 mM D,L-Hcy
and analyzed for RhoA translocation and activity, Rho
Kinase (ROCK) activity and expression and flippase
activity. In addition, the effect of ROCK inhibition with
Y27632 on Hcy-induced PS exposure and flippase
activity was analyzed. Furthermore, GTP and ATP
levels were determined. Results: Incubation of H9c2
cells with 2.5 mM D,L-Hcy did not inhibit RhoA
translocation to the plasma membrane. Neither did it
inhibit activation of RhoA, even though GTP levels
were significantly decreased. Hcy did significantly
inhibit ROCK activation, but not its expression, and
did inhibit flippase activity, in advance of a significant
decrease in ATP levels. ROCK inhibition via Y27632
did not have significant added effects on this.
Conclusion: Hcy induced PS exposure in the outer
leaflet of the plasma membrane in cardiomyocytes
via inhibition of ROCK and flippase activity. As such
Hcy may induce cardiomyocytes vulnerable to
inflammation in vivo in hyperhomocysteinaemia
patients.
Introduction
Homocysteine (Hcy) is an amino acid derived from
the methionine metabolism and is normally remethylated
to methionine or otherwise converted to cysteine. Due to
either genetic mutations in the converting enzymes or due
to shortages of vitamin B6, B12 or folate which are
important co-factors in the metabolism, Hcy levels can
rise [1]. For instance, genetic mutations in the cysthatione
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β–synthase (CBS) gene can result in highly increased
Hcy plasma levels of up to 400 µM, which is known as
hyperhomocystinuria [2]. These patients usually develop
severe cardiovascular complications as young adults.
Most patients however suffer from moderately increased
levels of Hcy, known as hyperhomocysteinaemia (HHC)
which are mostly caused by co-factor shortages.
Population studies have revealed that HHC, even in mild
forms can be an independent risk factor for the
development of atherosclerosis and heart failure [3-5].
HHC has been shown to induce heart failure including
diastolic and systolic dysfunction, with myocardial fibrosis
and subsequent ventricular hypertrophy and increased
wall thickness [5-7]. The mechanisms underling this
HHC-induced heart failure however remain for a large
part unknown.
Previously we have demonstrated that Hcy induced
apoptosis and necrosis, but also reversible exposure of
phosphatidylserine in the outer plasma membrane leaflet
in cardiomyocytes (PS exposure)  [8]. In eukaryotic cells
plasma membrane phospholipids are distributed
asymmetrically in the bilayer. The outer leaflet
predominantly contains phosphatidyl-choline (PC),
whereas anionic PS and phosphatidyl-ethanolamine (PE)
are kept within the inner leaflet [9]. Exposure of PS in
the outer plasma membrane leaflet occurs in apoptotic
cells, but can also be reversible and occur independently
of apoptosis [10]. Exposed PS becomes a target for
inflammation, and we have shown previously that in the
presence of inflammation, reversible PS exposure can
result in additional cardiomyocyte death after myocardial
infarction [11, 12]. This Hcy-induced (reversible) PS
exposure by cardiomyocytes, thereby facilitating local
inflammation and resulting cardiomyocyte death,
potentially also is a contributing factor to HHC-induced
heart failure.
We have recently found that inhibition of Rho -
ROCK signaling induced both apoptotic and non-apoptotic
PS exposure in cardiomyocytes via inhibition of
flippase [13]. Flippase is an ATP-dependent
transmembrane protein that has been found to regulate
transbilayer phospholipid asymmetry also in
cardiomyocytes, by translocating PS from the outer to
the inner membrane layer [14]. This study showed a
regulatory role for a novel signaling route, Rho - ROCK
- flippase signaling, in maintaining asymmetrical membrane
phospholipid distribution in cardiomyocytes. In the present
study we have investigated the possible involvement of
this signaling route in Hcy-induced PS exposure in
cardiomyocytes.
Materials and Methods
Cell culture
Rat cardiomyoblasts (H9c2 (2-1) cells; ATCC, Manassas,
VA, USA) were cultured in Dulbecco’s Modified Eagles Medium
(DMEM; BioWhittaker, Verviers, Belgium) supplemented with
10% heat-inactivated fetal calf serum (FCS; BioWhittaker), 2
mM L-glutamine (GIBCO, Paisley, UK), 100 IU/ml penicillin
(Yamanouchi Europe BV, Leiderdorp, Netherlands) and 100 µg/
ml streptomycin (Radiopharma-Fisiopharma, Palomonte, Italy),
and grown at 37°C in a humidified 5% CO2/95% air atmosphere.
Experiments were performed with cells grown to a confluency
of 60 - 80%.
Cells were incubated with 2.5 mM D,L-homocysteine (Hcy)
(Sigma, St. Louis, MO, USA) in growth medium for 14, 18 or 24
hours at 37°C in a humidified 5% CO2/95% air atmosphere,
according to our previous study [8]. Cells were incubated with
ROCK inhibitor 10 μM Y27632 (Calbiochem, Nottingham, UK)
for 24.5 hours at 37°C in a humidified 5% CO2/95% air
atmosphere. In case cells were co-incubated with Y27632 and
Hcy, Y27632 was added to cells 30 minutes prior to Hcy.
Flow cytometry
PS exposure was assessed with FITC-labeled human
recombinant annexin-V (Bender Med Systems, Vienna, Austria),
while propidium iodide (PI; Bender Med Systems) was used to
determine the permeability of the cellular membrane.
Experiments were performed in the presence or absence of Z-
Asp-Glu-Val-Asp-fluoromethylketone (Z-VAD FMK, 25 μM,
Alexis Biochemicals, Lausen, Switzerland), a general caspase
inhibitor, to differentiate between reversible and irreversible
PS exposure.
After treatment with Hcy, the cells were trypsinized and
centrifuged at 400xg for 5 minutes at room temperature. Cells
were then washed with serum-free DMEM, and resuspended
in serum free DMEM containing annexin V (1:40) for 30 minutes
in the dark at 37°C in a humidified 5% CO2/95% air atmosphere.
Cells were subsequently washed and resuspended in serum
free DMEM containing PI (1:40), and were measured with a
FACSCalibur (Becton Dickinson, San Jose, CA, USA). Results
were analyzed by Cell Quest Pro software (Becton Dickinson).
To determine flippase activity, cells were harvested after
incubation with or without Hcy and resuspended in serum free
DMEM medium. NBD labeled phosphatydylserine (PS-NBD:
(1-palmitoyl-2-[6-[ (7-ni t ro-2–1,3-benzoxadiazol-4-
yl)amino]caproyl]-sn-glycero-3-phosphoserine) (Avanti Polar
Lipids, Alabaster, AL, USA) was added in a final concentration
of 1 μmol/L at 37°C for 30 minutes. The cells were then transferred
to ice and 5 ml ice-cold 1% (w/v) BSA in PBS added to wash
away excess probe. After 15 minutes the cells were pelleted
and resuspended in serum-free culture medium and then
analyzed by flow cytometry (FACSCalibur). With each
experiment, part of the harvested cells were analyzed for
membrane flip flop as described before.
To determine whether the PS-NBD negative cells are in
fact annexin V positive, the cells were labeled with Cy5-labeled
annexin V for 15 minutes at 37°C subsequent to PS-NBD staining
and measured at once as described before.
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Determination of ATP and GTP levels
After treatment, 5 x 10E6 cells per condition were
centrifuged at 400 x g for 2 minutes. The pellet was resuspended
in 150 µl of ice-cold perchloric acid (PCA) 0.4 M, kept on ice for
30 minutes and subsequently centrifuged at 200 x g for 5 minutes
at 4°C. To the isolated supernatant 7.5 µl of K2CO3 5 M was
added to neutralize pH. Samples were subsequently stored at -
80°C. ATP levels were determined using a Luciferase-Luciferin
assay (Biaffin GmbH & Co KG, Kassel, Germany) according to
the manufacturers’ protocol. Samples were analyzed in a
FluoroNunc MaxiSorp plate (Nalge Nunc International,
Rochester, NY). Luminescence was measured in a Tecan GENios
Plus reader (Tecan Benelux, Mechelen, Belgium). GTP levels
were determined using High Pressure Liquid Chromatography
(HPLC) as described before [15]. The columns used were
prepacked Partisphere (partisil-5) SAX cartridges (4.6 x 125 mm
internal dimensions; Whatman Int. Ltd., Maidstone England).
The GTP concentrations were calculated by comparison with
highly purified standards (Sigma).
RhoA activity assay
RhoA activity was determined in H9c2 cell protein extracts,
using the luminescence-based G-LISATM RhoA activation assay
biochemistry kit (Cytoskeleton, Inc. Denver, CO, USA)
according to the manufacturer’s instructions. Protein
concentration was determined according to the manufacturer’s
protocol, and cell extracts were equalized. Samples were
measured in a FluoroNunc MaxiSorp plate (Nalge Nunc
International).
Cell fractioning and Western Blot analysis
For whole cell lysates, cells were harvested into modified
ELB lysis buffer (250 mM NaCl, 0.1% Nonidet P-40, 50 mM
HEPES pH 7.0, 5 mM EDTA, 0.5 mM DTT) with added protease
inhibitor cocktail (PIC, 1:25; Sigma), mixed thoroughly and then
incubated on ice for 30 minutes. To obtain membrane and
cytosolic fractions, cells were harvested into lysis buffer (5
mM Tris, 1 mM EDTA, 5 mM MgCl2) and homogenized using a
dounce tissue grinder (Wheaton, Millville, NJ, USA). Samples
were centrifuged at 500 x g for 5 minutes at 4°C. The supernatant
was then centrifuged at 40,000 rpm using a Beckman centrifuge
(50 Ti rotor; BeckmanCoulter, Mijdrecht, The Netherlands) for
20 minutes at 4°C to separate the membrane fraction (pellet)
from the cytosolic fraction (supernatant). The membrane fraction
was dissolved in incubation buffer (25 mM Tris, 1 mM EGTA,
20 mM MgCl2). After determination of the protein concentration
with the BCA protein assay kit (Pierce, Rockford, IL, USA), the
samples were diluted in β-mercaptoethanol-containing sodium
dodecylsulfate (SDS) sample buffer. 20 μg protein of each
sample was then subjected to SDS-PAGE, blotted onto
nitrocellulose membranes and analyzed for RhoA, ROCK-1 and
ROCK-2 expression using mAb against RhoA (26c4; 1:100
dilution; Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA),
mAb against ROCK-1 (G-6; 1:250 dilution; Santa Cruz) or pAb
(goat) against ROCK-2 (C-20; 1:400 dilution; Santa Cruz),
followed by horseradish-peroxidase-conjugated rabbit-anti-
mouse immunoglobulins (RαM-HRP; 1:1000 dilution;
DakoCytomation, Glostrup, Denmark) for RhoA and ROCK-1
or Swine-anti-Goat-HRP (1:500 dilution; DakoCytomation) for
ROCK-2. The blots were visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences AB; Uppsala;
Sweden). Staining was quantified with a charge-coupled device
camera (Fuji Science Imaging Systems; Düsseldorf, Germany)
in combination with AIDA Image Analyzer software
(Isotopenmessgeräte; Staubenhardt, Germany). For detection
of total and phosphorylated ezrin, radixin and moesin (ERM)
proteins, rabbit pAbs against total ERM and phospho-ERM
were used (both 1:1000 dilution; Cell Signaling Technology,
Inc) followed by swine-anti-rabbit-HRP (1:1000;
DakoCytomation).
Digital imaging fluorescent microscopy of RhoA
Cells were cultured in Lab-Tek II 4-well chamber CC2 glass
slides (Nalge Nunc International, Naperville, IL, USA). After
Fig. 1. Effect of Hcy on cell viability. Cell
viability of H9c2 cells, incubated for 24 hours
with (Hcy) or without (control) 2.5 mM D,L-
Hcy. (A) percentage of viable cells,
*p<0.0001; (B) percentage of single annexin
V positive cells, *p<0.0001; (C) percentage
of annexin V/PI positive cells, *p<0.02; (D)
percentage of single PI positive cells. Data
represent mean ± SEM (n=10).
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treatment, cells were fixed with 4% paraformaldehyde for
10 minutes at 37°C, then permeabilized with 0.2% Triton for
10 minutes at RT and subsequently incubated with mAb
against RhoA (26c4; 1:50 dilution; Santa Cruz) for 1 hour at RT
followed by incubation overnight at 4°C. The cells were
then incubated with Cy3-labeled Goat-anti-mouse
immunoglobulins (Invitrogen Corporation, Carlsbad, CA, USA)
for 30 min at RT in the dark. Negative controls with
only the secondary antibody were included to assess nonspe-
cific binding. All negative controls showed no staining (data
not shown). Before visualization, HardSet mounting medium
containing 4',6-diamidino-2-phenylindole (DAPI; H-1500,
Vector Laboratories Inc, Burlingame, CA, USA) was added and
the cells were covered. The cells were analyzed with a
3I MarianasTM digital-imaging microscopy workstation
(Zeiss Axiovert 200 M inverted microscope; Cark Zeiss,
Sliedrecht, The Netherlands) equipped with a thermo-electri-
cally cooled EMCCD camera (QuantEM: 512C, 512x512 pixels;
Photometrics, Tucson, AZ, USA). Data was processed with
SlidebookTM software (version 4.2; Intelligent Imaging Innova-
tions, Denver, CO, USA).
Statistics
Statistics were performed with the SPSS statistical program
(windows version 15.0). To evaluate whether observed
differences were significant, independent student T-tests or
One Way ANOVA with post hoc Bonferroni tests were used.
In the text and relevant figures values are given as means ± SD.
A p-value (two-sided) of 0.05 or less was considered to
represent a significant difference.
Fig. 2. Effect of Hcy on RhoA
location and activity. H9c2 cells
were incubated for 24 hours with
(Hcy) or without (control) 2.5 mM
D,L-Hcy and presence of RhoA
(24 kDa) was determined and
quantified (Lau= light arbitrary
units) in isolated cytosol and
membrane fractions via western
blot analysis (n=4). (A) cytosol
fractions, diluted in 2 ml, Lau
recalculated to 10 µl. (B)
Membrane fractions; diluted in
150 µl, Lau (Light arbitrary unit)
recalculated to 10 µl. (C) Digital
imaging fluorescent microscopy
analysis of RhoA in H9c2 cells
that were incubated for 24 hours
with (Hcy) or without (control)
2.5 mM D,L-Hcy. Arrowheads
indicate membranous RhoA
localization. (D) GTP levels were
determined in whole cell lysates
of control cells and cells
incubated with 2.5 mm D,L-Hcy
for 24 hours (n=4). (E) RhoA
activity was determined in whole
cell lysates of control cells and
cells incubated with 2.5 mm D,L-
Hcy for 24 hours (n=3). Data
represent mean ± SEM.
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Results
Hcy induced PS- exposure
We first wanted to validate our previous finding of
induced PS exposure in H9c2 cells by 2.5 mM D,L-Hcy
for 24 hours [8]. We found a significant decrease of viable
cells from 77.5 ± 2.4% in control cells to 54.9 ± 3.7% in
Hcy treated cells (Fig. 1A; *p<0.0001; n=10) and a
significant increase of single annexin V-positive cells from
5.8 ± 1.2% in control cells to 20.6 ± 2.2% in Hcy treated
cells (Fig. 1B; *p<0.0001; n=10). We also found a
significant increase in annexin V/PI-positive cells from
13.8 ± 1.4% in control cells to 20.9 ± 2.5% in Hcy treated
cells (Fig. 1C; *p<0.02) and a minor, non-significant
increase of single PI-positive cells from 1.7 ± 0.3% in
control cells to 3.2 ± 1.0% in Hcy treated cells (Fig. 1D).
The induction of single annexin V-positive cells induced
by Hcy was not inhibited by Z-VAD fmk (data not
shown), this indicates reversible PS exposure, as shown
previously [8].
Effect of Hcy on RhoA location and activity
We have recently found that inhibition of Rho protein
activity by Toxin B and exoenzyme C3 transferase
resulted in PS exposure in H9c2 cells [13]. To determine
whether Hcy-induced PS-exposure results from an effect
on Rho - ROCK signaling, we first examined whether
Hcy affects RhoA translocation -via cell fractioning - and
activity - via cellular GTP measurements and a RhoA
activity assay.
In control cells, RhoA was mainly present in the
cytosolic fraction (Fig. 2A, B; intensity of the bands was
defined as light arbitrary units (Lau); n=4). Notably, via
immunoblotting two bands were detected, indicative for
Fig. 3. Effect of Hcy on ROCK activity and expression. (A) Western blot analysis for phosphorylated ERM (pERM) and total
ERM (tERM) of H9c2 cells incubated with (Hcy) or without (control) 2.5 mM D,L-Hcy for 24 hours. (B) Quantification of the
intensity of the bands is shown in the graph where the amount of pERM was calculated in comparison with tERM, and the control
was set to 1. *p<0.002. (C) Western blot analysis for ROCK-1 and ROCK-2 in H9c2 cells incubated with (Hcy) or without (control)
2.5 mM D,L-Hcy for 24 hours. Quantifications of the protein bands are shown in the graphs (Lau= light arbitrary units). (D)
Percentages of single-annexin V-positive H9c2 cells, incubated with Hcy, with Y27632 or both. ‡p<0.001, *p<0.05, †p<0.05. Data
represent mean ± SEM (n=4).
A B
C D
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RhoA (24 kD) and the calpain cleaved form RhoA (20
kD), which has lost its normal RhoA function as described
before [16]. For this, we only quantified the 24 kD RhoA
band. Hcy induced a non-significant decrease in RhoA in
the cytosolic fraction and a clear but nonsignificant
increase in RhoA in the membrane fraction (Fig. 2A, B),
indicating that Hcy did not inhibit RhoA translocation to
the plasma membrane. Although the Hcy effects were
not significant, we found this Hcy-induced RhoA
translocation to the membrane fraction in each of the
four independent experiments. These results were
confirmed via digital imaging fluorescent microscopy (Fig.
2C). In control cells, RhoA was found mainly in the
cytosol, whereas Hcy induced a marked increase in RhoA
located at the plasma membrane (arrowheads).
In addition to membrane-anchorage, RhoA needs
GTP for its activity. We therefore also determined the
effects of Hcy on cellular GTP levels. Incubation with
Hcy induced cellular GTP levels to decrease significantly
from 437 pmol/106 cells in control cells to 262 pmol/106
cells in Hcy treated cells (Fig. 2D; p=0.05; n=4).
Notwithstanding this decrease there was still considerable
residual cellular GTP. To analyze whether this residual
GTP still is sufficient for RhoA activation, a RhoA activity
assay was performed. RhoA activity in cells incubated
with Hcy did not differ significantly from control cells
(Fig. 2E; n=3). From these data we can conclude that
Hcy does not inhibit RhoA.
Fig. 4. Effect of Hcy on flippase activity.
Flow cytometry analysis of flippase
activity in H9c2 cells incubated with or
without 2.5 mM D,L-Hcy for 24 hours
using PS-NBD. (A) Dot plots show PS-
NBD positivity against cell size (FSH-
Height). (B) percentage of PS-NBD
negative cells in control cells and Hcy-
treated cells. *p=0.033. Data represent
mean ± SEM (n=10). (C) Percentages of
NBD-negative H9c2 cells, incubated with
Hcy, with Y27632 or both. *p<0.05,
†p<0.01. Data represent mean ± SEM
(n=4).
Effect of Hcy on ROCK activity
ROCK is a downstream effector of RhoA.
Previously we have shown that inhibition of Rho-kinase
with the specific ROCK inhibitors Y-27632 and H1152
induced PS exposure in non-ischemic cardiomyocytes
[13]. We analyzed a putative effect of Hcy on ROCK
activity and expression. As ROCK phosphorylates the
ezrin, radixin and moesin (ERM) proteins [17], Rho-kinase
activity can be determined by measuring the level of
phosphorylation of ERM (pERM).
Incubation with Hcy for 24 hours induced a
significant decrease of 45% in ERM phosphorylation (Fig.
3A, B; SD ± 9.540; *p=0.002; n=4), determined as the
relative amount of phosphorylyzed ERM (pERM) related
to the total amount of ERM (tERM). These data thus
indicate that Hcy inhibits ROCK activity. This inhibitory
effect of Hcy on ROCK activity may relate to an inhibitory
effect on ROCK expression. Therefore, ROCK-1 and
ROCK-2 expression levels were analyzed via Western
blot. There was no significant effect of Hcy on the
expressions of ROCK-1 and ROCK-2, although Hcy
treatment appeared to lower the expression levels of
ROCK-2 (Fig. 3C).
In addition, the effect of (pre-)inhibition of ROCK
on Hcy-induced PS exposure was analyzed, using the
ROCK inhibitor Y27632. As reported previously [13],
Y27632 induced a significant increase in single-annexin
V-positive cells to 19.9 ± 2.6% compared to 8.1 ± 2.1%
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Fig. 5. Flippase activity and ATP
dependency. Flow cytometry analysis of
flippase activity and determination of
cellular ATP levels in H9c2 cells
incubated with or without 2.5 mM D,L-
Hcy for 14 and 18 hours using PS-NBD.
(A) percentage of PS-NBD negative cells,
*p<0.01 vs control, †p<0.001 vs control;
(B) ATP levels, *p<0.05 vs control. Data
represent mean ± SEM (n=6).
Fig. 6. Flippase activity and PS exposure. Flow cytometry
analysis of H9c2 cells that were incubated without (control) or
with 2.5 mM D,L-Hcy for 24 hours. Cells were then incubated
with PS-NBD and subsequently with Cy5-labeled annexin V.
Shown is the relative size of the PS-NBD-negative/Annexin V-
positive cell population. *p=0.022. Data represent mean ± SEM
(n=4).
in control cells (*p<0.05; Fig. 3D). Y27632 pre-treatment
followed by Hcy incubation also induced a significant
increase in single-annexin V-positive cells to 23.9 ± 1.8%
(†p<0.05), but this percentage of single-annexin V-positive
cells did not differ significantly from that induced by
Y27632 alone. The percentage of single-annexin V-
positive cells induced by Hcy alone (30.4 ± 3.1%;
‡p<0.001 vs control) was higher than those induced by
Y27632 alone or Y27632 followed by Hcy, but not
significantly. These results support a role for ROCK
inhibition in Hcy-induced exposure of PS.
Effect of Hcy on flippase activity
We then wanted to determine whether the inhibitory
effect of Hcy on ROCK activity also affected flippase
activity. Flippase activity was determined by flow
cytometry analysis using NBD-labeled PS. In cells with
flippase activity this PS-NBD is internalized resulting in
PS-NBD-positive cells, whereas cells with inactive
flippase will not internalize PS-NBD and remain PS-
NBD-negative [13] (Fig. 4A).
Hcy induced a significant increase in the amount of
PS-NBD-negative cells, form 16 ± 3% in control cells to
27 ± 4% (Fig. 4B; *p=0.033; n=10), indicating that Hcy
significantly decreased flippase activity. In addition, the
effect of (pre-)inhibition of ROCK on Hcy-induced
flippase activity was analyzed. Y27632 induced a
significant increase in PS-NBD-negative cells to 32.1 ±
3.3% compared to 17.3 ± 1.8% in control cells (*p<0.05;
Fig. 4C). Y27632 pre-treatment followed by Hcy
incubation also induced a significant increase in PS-NBD-
negative cells to 36.3 ± 4.8% (†p<0.01), but this
percentage of PS-NBD-negative cells did not differ
significantly from that induced by Y27632 alone, again
supporting a role for ROCK inhibition in Hcy-induced
inhibition of flippase.
As flippase activity is ATP dependent [18], we
analyzed whether Hcy-induced flippase activity is caused
by ATP. Flippase activity and cellular ATP levels were
determined at several time points during the total Hcy
incubation period of 24 hours. A significant decrease in
flippase inactivity was measured after 14 hours of Hcy
incubation (Fig. 5A; *p<0.01), at which time-point cellular
ATP levels were comparable with those in control cells
(Fig. 5B). A significant decrease in cellular ATP occurred
only after 18 hours of Hcy incubation (Fig. 5B; *p<0.05).
Therefore, Hcy-induced flippase inhibition is not due to a
lack in cellular ATP.
To establish whether this flippase inactivation
coincided with PS exposure, double stainings were
performed with PS-NBD and Cy5-labbeled annexin V.
Incubation with Hcy indeed resulted in a population of
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cells that were PS-NBD negative but annexin V-positive
(Fig. 6; *p=0.022; n=4), indicating that Hcy-induced
flippase inactivity coincided with PS exposure.
Discussion
We were the first to describe that Hcy induced
apoptosis, necrosis but also reversible PS exposure in
cardiomyocytes [8]. In the present study, we analyzed
the mechanism(s) through which Hcy induced this PS
exposure in cardiomyocytes. We have found that Hcy
induced inhibition of Rho-kinase activity and flippase
activity (Fig. 7) which to the best of our knowledge has
never been described before.
In a previous study we found that impaired Rho –
ROCK signaling resulted in PS exposure in the outer
plasma membrane leaflet in cardiomyocytes [13]. This
concurs with the findings of Grounds et al. who showed
that inhibition of Rho activity by the Rho(A,B,C) specific
inhibitor exoenzym C3 transferase induced annexin V
positivity [19]. In the present study however we found
that although Hcy did induce RhoA translocation to the
plasma membrane, it did not alter RhoA activity, indicating
that the Hcy-induced PS exposure occurred independent
of impaired RhoA. On the other hand, Hcy did inhibit
ROCK activity resulting in decreased phosphorylation of
the ERM proteins. As Hcy did not significantly decrease
the expression of ROCK-1 and ROCK-2, this inhibitory
effect of Hcy on ROCK activity appears to be due mainly
to blocking of its activity. Since Hcy did appear to lower
the expression levels of ROCK-2, we cannot rule out a
partial effect of decreased ROCK-2 expression on Hcy-
induced ROCK inactivation. Previously we showed that
inhibition of ROCK via Y27632 or H1152 did lead to PS
exposure [13]. Here we show that inhibition of ROCK
via Y27632, did not significantly affect Hcy-induced PS
exposure, indeed supporting a role for ROCK inhibition
in Hcy-induced PS exposure.
As we have previously shown, PS exposure
represents a pro-inflammatory status of the cell [12]. This
suggests that Hcy induced inhibition of Rho-kinase would
put cardiomyocytes at risk as targets for inflammation.
In the past several rat and mice in vivo studies have
been performed in which the effect of commercially
available ROCK inhibitors was analyzed related to the
prevention of vascular endothelial disease independent
of Hcy [20-23]. However, in none of these studies the
effect on PS exposure in cardiomyocytes and/or
replacement fibrosis was studied as a measure of putative
loss of cardiomyocytes. Therefore, our in-vitro findings
suggesting a jeopardizing effect of inhibition of Rho-kinase
on cell viability of cardiomyocytes still have to be
extrapolated in-vivo.
Hcy inhibited flippase activity in cardiomyocytes, in
advance of a decrease in ATP, suggesting that Hcy does
so through mechanisms independent of ATP. We have
shown earlier that ROCK inhibitors Y27632 and H1152
did inhibit flippase activity without altering cellular ATP
levels [13]. In this study we additionally show that
inhibition of ROCK via Y27632, did not significantly affect
Hcy-induced inhibition of flippase activity. This suggests
that Hcy inhibits flippase via its inhibitory effect on
ROCK.
A limitation of the present study is the use of
relatively high concentrations of Hcy. However, in our
Fig. 7. Hypothetic scheme for Hcy
induced PS exposure via ROCK
inactivation. The scheme shows that Hcy
induces RhoA translocation to the
plasma membrane (green arrow); Hcy
directly inhibits ROCK activity (in black,
blocking line); Hcy inhibits flippase
activity via ROCK, although we cannot
exclude the possibility of an Hcy effect
on flippase activity independent of
ROCK (in black, blocking line with ?);
Hcy also depletes ATP and GTP levels,
but only partly (in black, broken blocking
line).
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that Hcy propagates inflammation in the heart by making
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increasing inflammatory activity.
In conclusion, we have now shown that Hcy induces
PS exposure in cardiomyocytes via inhibition of Rho-
kinase and flippase activity. As such Hcy may induce
cardiomyocytes vulnerable to inflammation in vivo in
HHC patients.
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